Loading…
← CockpitCompetitor Analysis › 603262.SS TSI Group Co., Ltd. Class AOpen in the cockpit ↗

TSI Group Co., Ltd. Class A603262.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Other

Nutraceutical ingredient maker known globally for myHMB, a branded muscle-health supplement ingredient sold to supplement brands.

≈ A Chinese-owned global sports-nutrition ingredient supplierMomentum laggard 16
Mkt cap
$842M
US dollars, full cap
$/day
$4.79M
20-day average traded
Fwd P/E
47.7×
forward earnings
ROIC−WACC
+4.8 pp
WACC 10.2%
Hurdle
+11 pp
Req g minus delivered
Next earnings
105 days
3 Mar 2027
Close · CNYCN¥14.19
1D-3.1%
1W-7.6%
1M-13.6%
3M-25.0%
6M-45.8%
YTD-50.2%
1Y-51.9%
ATR %3.5%
52w lowhigh55.2% off high

What TSI does

Nutraceutical ingredient maker known globally for myHMB, a branded muscle-health supplement ingredient sold to supplement brands.

Sells its HMB ingredient, a muscle-health compound, to supplement brands that put it in their own products, so revenue follows brand customers' reorders and the standing of the myHMB name, which is backed by published studies. It is an ingredient supplier, not a consumer brand.

In one line: A Chinese-owned global sports-nutrition ingredient supplier.

Products and services

  • myHMB (beta-hydroxy-beta-methylbutyrate)
  • Other nutraceutical ingredients

Customers

  • Global supplement and sports-nutrition brands

Where it sits in the supply chain

  • Nutrition ingredients
  • Nutraceuticals
  • Branded sports-nutrition ingredients

What could go right

  • Global sports-nutrition and healthy-aging demand

What could go wrong

  • Generic HMB competition
  • Raw-material cost swings

Moat: narrow (brand, IP / patents). Patented branded ingredient with clinical research backing gives pricing power over generic HMB.

Headquarters: Shanghai, China · Employees: 829

Named competitors

TSI at a glance

Size TSI (603262.SS) is a China Health Care company (Pharmaceuticals: Other) with a market value of $842M, the 2490th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥14.19 on 18 Nov 2026.

Performance Over six months the shares fell 45.8%, against -18.4% for the median peer and -20.0% for the China market (cap-weighted) — lowest of 21 in its peer set.

Growth Revenue grew 3.1% over the last twelve months (peer median +3.5%); the operating margin is 13.6% (peer median 12.6%).

Valuation It trades at 47.7× forward earnings against a peer median of 20.0× (3rd most expensive of 16).

Price implies For today's price to make sense, revenue must grow about 24% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is +11 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 4.8 points above its cost of capital (10.2% WACC).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010012021 May 202621 Aug 202618 Nov 2026Peer median 82603262.SS 53
Six months, rebased to 100: TSI against the median of its 20 peers (local-currency closes).

TSI financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2021FY2020
RevenueCN¥1.09BCN¥1.09BCN¥999MCN¥801MCN¥746M
Revenue growth—+9%+25%+7%—
Gross profitCN¥504MCN¥445MCN¥419MCN¥292MCN¥281M
EBITDAn/aCN¥192MCN¥238MCN¥171MCN¥101M
Net incomeCN¥116MCN¥134MCN¥174MCN¥110MCN¥46.8M
Free cash flowCN¥20.5M-CN¥30.0MCN¥122MCN¥22.3MCN¥77.3M
Capital expenditureCN¥218MCN¥182MCN¥105MCN¥90.6MCN¥47.1M
Total debtCN¥76.3MCN¥85.0MCN¥75.3MCN¥225MCN¥227M

Quarterly statements and history in the cockpit →

TSI competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%-10%0%0460PHN2877300791002219APN60048830003900075600227500256230015821420775CRON300261PHM301507BIOG-B6472603262.SS6-month return →1-month return →
Up and to the right = strong over both horizons. TSI is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%+40%+60%0×200×400×0460PHN2877300791002219APN0007562142300261PHM301507BIOG-B6472603262.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. TSI is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%20%40%60%PHN300791APN6004883000390007560022752142CRONPHM301507BIOG-B6472603262.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. TSI is the large dot.

TSI competitors and peer comparison

Head to head with its named competitors (603262.SS vs LONN.SW vs 4151.T)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
TSI 603262.SS$842M-46%+3%14%47.7×24.3%
Lonza LONN.SW$53.9B+36%-11%25%36.1×15.6%
Kyowa Kirin 4151.T$8.43B+9%+10%24%16.4×-4.7%

How TSI compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

TSI against its 20 peers (data as of 18 Nov 2026)
Measure603262.SSPeer medianRank in peer set
1-month return-13.6%-7.3%3rd lowest of 21
6-month return-45.8%-18.4%lowest of 21
Distance from 52-week high-55.2%-39.3%2nd lowest of 21
Revenue growth (TTM)+3.1%+3.5%11th highest of 21
Operating margin13.6%12.6%11th highest of 21
Forward P/E47.7×20.0×3rd most expensive of 16
Growth the price implies (Req g, 7 yrs)24.3%4.4%2nd most demanding of 15
Growth delivered (Del g)+13.4%+14.5%7th lowest of 15
Hurdle (Req g minus delivered)+11.0 pp-8.7 pp2nd most demanding of 15
ROIC minus cost of capital+4.8 pp+0.7 pp8th highest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
TSI 603262.SSChina$842M-46%+3%14%47.7×24.3%+13.4%
Sihuan Pharmaceutical 0460.HKHong Kong$856M-34%+30%15%8.7×n/an/a
PharmaNutra PHN.MIItaly$922M+2%+17%22%33.5×4.7%+18.5%
China Shineway Pharmaceutical 2877.HKHong Kong$760M-8%-18%25%7.6×n/an/a
Sirio Pharma 300791.SZChina$759M-6%-9%1%16.2×14.1%+15.6%
New Journey Health Technology Group Co., Ltd.Class A 002219.SZChina$942M-18%-14%8%182.0×n/an/a
Applied Nutrition APN.LUnited Kingdom$986M+31%+51%25%21.4×24.6%+38.5%
Tianjin Tianyao Pharmaceuticals 600488.SSChina$718M-36%-12%3%n/a2.1%-1.3%
Shanghai Kaibao Pharmaceutical 300039.SZChina$703M-20%-14%22%n/a0.4%+4.8%
Shandong Xinhua Pharmaceutical 000756.SZChina$1.01B-17%-5%4%20.0×0.5%+7.9%
Guilin Sanjin Pharmaceutical 002275.SZChina$1.05B-12%-3%24%12.8×-8.7%+5.5%
Brother Enterprises 002562.SZChina$668M-33%+8%4%n/a4.0%+13.5%
Shanxi Zhendong Pharmaceutical 300158.SZChina$641M-22%-28%-25%n/an/an/a
HBM 2142.HKHong Kong$1.12B-18%+55%44%11.7×13.1%+62.3%
CK Life Sciences International (Holdings) 0775.HKHong Kong$613M-30%0%0%n/an/an/a
Cronos CRON.TOCanada$1.17B+24%+55%5%16.2×18.8%+26.7%
ABA Chemicals 300261.SZChina$592M-26%-16%-23%405.0×n/an/a
Pharma Mar PHM.MCSpain$1.21B-38%+32%19%41.4×10.6%-3.9%
Hangzhou Minsheng Healthcare 301507.SZChina$583M-23%+21%11%45.4×19.1%+12.1%
BioGaia BIOG-B.STSweden$1.25B-4%+13%28%31.0×1.5%+15.5%
Bora Pharmaceuticals 6472.TWTaiwan$1.25B-2%+7%14%10.8×3.5%+60.2%

Questions

Who are TSI's main competitors?
Named competitors: Lonza (LONN.SW), Kyowa Hakko Bio (4151.T). The cockpit's measured peer set (industry) also includes Sihuan Pharmaceutical (0460.HK), PharmaNutra (PHN.MI), China Shineway Pharmaceutical (2877.HK), Sirio Pharma (300791.SZ), New Journey Health Technology Group Co., Ltd.Class A (002219.SZ), Applied Nutrition (APN.L).
Is TSI expensive compared with its peers?
On forward p/e it trades at 47.7× against a peer median of 20.0×, 3rd most expensive of 16 in its peer set. For today's price to make sense, revenue must grow about 24% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is +11 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has TSI stock performed?
Over six months to 18 Nov 2026 the shares returned -45.8% against -18.4% for the median peer; over one year -51.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.